Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
Cancer Medicine

A prospective, multicenter analysis of recurrence-free survival after sentinel lymph node biopsy decisions influenced by the 31-GEP

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of recurrence-free survival after sentinel lymph noide biopsy decisions influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839. doi: 10.1002/cam4.70839

View PublicationResults
Background

Sentinel lymph node biopsy (SLNB) helps assess melanoma recurrence risk but is often unnecessary, with up to 88% of results returning negative, leading to avoidable costs and complications. Traditional SLNB decision-making relies solely on clinicopathologic factors, which fail to identify some patients at risk of recurrence. The 31-gene expression profile (31-GEP) test objectively stratifies risk, identifying patients with <5% likelihood of SLN positivity who may safely forego SLNB. Studies suggest 31-GEP testing improves survival outcomes and enables earlier recurrence detection.

‍

objective

To assess recurrence in patients who would have been recommended to forego SLNB based on low-risk (Class 1A) 31-GEP results. We assessed whether these patients experienced any recurrence, particularly early recurrences, regardless of whether an SLNB was performed or SLNB positivity.

‍

methods

The DECIDE study is a prospective, multi-center study evaluating SLNB-eligible patients with T1-T2 tumors who underwent 31-GEP testing. Conducted across 22 institutions from May 2020 to May 2022, the study included patients whose clinicians considered SLNB and ordered the 31-GEP test for clinical decision-making. Data collection included 31-GEP results, SLNB performance, and recurrence outcomes, recorded through chart reviews and participant follow-ups at six-month intervals. This analysis focuses on early recurrence-free survival (RFS) in patients with Class 1A 31-GEP results who opted out of SLNB, ensuring these patients were not harmed by avoiding the procedure.

‍

Results

The current study demonstrates that patients with a Class 1A result may safely forgo the SLNB procedure. No patients had a recurrence within the study period, regardless of SLN status, supporting the clinical value of the 31-GEP test in guiding patient care.

‍

Want to learn more about
DecisionDx-Melanoma?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
Cancer Medicine

A prospective, multicenter analysis of recurrence-free survival after sentinel lymph node biopsy decisions influenced by the 31-GEP

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of recurrence-free survival after sentinel lymph noide biopsy decisions influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839. doi: 10.1002/cam4.70839

View PublicationResults
Background

Sentinel lymph node biopsy (SLNB) helps assess melanoma recurrence risk but is often unnecessary, with up to 88% of results returning negative, leading to avoidable costs and complications. Traditional SLNB decision-making relies solely on clinicopathologic factors, which fail to identify some patients at risk of recurrence. The 31-gene expression profile (31-GEP) test objectively stratifies risk, identifying patients with <5% likelihood of SLN positivity who may safely forego SLNB. Studies suggest 31-GEP testing improves survival outcomes and enables earlier recurrence detection.

‍

objective

To assess recurrence in patients who would have been recommended to forego SLNB based on low-risk (Class 1A) 31-GEP results. We assessed whether these patients experienced any recurrence, particularly early recurrences, regardless of whether an SLNB was performed or SLNB positivity.

‍

methods

The DECIDE study is a prospective, multi-center study evaluating SLNB-eligible patients with T1-T2 tumors who underwent 31-GEP testing. Conducted across 22 institutions from May 2020 to May 2022, the study included patients whose clinicians considered SLNB and ordered the 31-GEP test for clinical decision-making. Data collection included 31-GEP results, SLNB performance, and recurrence outcomes, recorded through chart reviews and participant follow-ups at six-month intervals. This analysis focuses on early recurrence-free survival (RFS) in patients with Class 1A 31-GEP results who opted out of SLNB, ensuring these patients were not harmed by avoiding the procedure.

‍

Results

The current study demonstrates that patients with a Class 1A result may safely forgo the SLNB procedure. No patients had a recurrence within the study period, regardless of SLN status, supporting the clinical value of the 31-GEP test in guiding patient care.

‍

Want to learn more about
DecisionDx-SCC?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
Cancer Medicine

A prospective, multicenter analysis of recurrence-free survival after sentinel lymph node biopsy decisions influenced by the 31-GEP

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of recurrence-free survival after sentinel lymph noide biopsy decisions influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839. doi: 10.1002/cam4.70839

View PublicationResults
Background

Sentinel lymph node biopsy (SLNB) helps assess melanoma recurrence risk but is often unnecessary, with up to 88% of results returning negative, leading to avoidable costs and complications. Traditional SLNB decision-making relies solely on clinicopathologic factors, which fail to identify some patients at risk of recurrence. The 31-gene expression profile (31-GEP) test objectively stratifies risk, identifying patients with <5% likelihood of SLN positivity who may safely forego SLNB. Studies suggest 31-GEP testing improves survival outcomes and enables earlier recurrence detection.

‍

objective

To assess recurrence in patients who would have been recommended to forego SLNB based on low-risk (Class 1A) 31-GEP results. We assessed whether these patients experienced any recurrence, particularly early recurrences, regardless of whether an SLNB was performed or SLNB positivity.

‍

methods

The DECIDE study is a prospective, multi-center study evaluating SLNB-eligible patients with T1-T2 tumors who underwent 31-GEP testing. Conducted across 22 institutions from May 2020 to May 2022, the study included patients whose clinicians considered SLNB and ordered the 31-GEP test for clinical decision-making. Data collection included 31-GEP results, SLNB performance, and recurrence outcomes, recorded through chart reviews and participant follow-ups at six-month intervals. This analysis focuses on early recurrence-free survival (RFS) in patients with Class 1A 31-GEP results who opted out of SLNB, ensuring these patients were not harmed by avoiding the procedure.

‍

Results

The current study demonstrates that patients with a Class 1A result may safely forgo the SLNB procedure. No patients had a recurrence within the study period, regardless of SLN status, supporting the clinical value of the 31-GEP test in guiding patient care.

‍

Want to learn more about
Mypath-Melanoma?

Contact Us
Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.Blue gradient background with vertical rounded lines in varying shades of blue scattered across the right side.
Clinical Summary
Cancer Medicine

A prospective, multicenter analysis of recurrence-free survival after sentinel lymph node biopsy decisions influenced by the 31-GEP

REFERENCE

Guenther, J.M., Ward, A., Martin, B.J. et al. A prospective, multicenter analysis of recurrence-free survival after sentinel lymph noide biopsy decisions influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839. doi: 10.1002/cam4.70839

View PublicationResults
Background

Sentinel lymph node biopsy (SLNB) helps assess melanoma recurrence risk but is often unnecessary, with up to 88% of results returning negative, leading to avoidable costs and complications. Traditional SLNB decision-making relies solely on clinicopathologic factors, which fail to identify some patients at risk of recurrence. The 31-gene expression profile (31-GEP) test objectively stratifies risk, identifying patients with <5% likelihood of SLN positivity who may safely forego SLNB. Studies suggest 31-GEP testing improves survival outcomes and enables earlier recurrence detection.

‍

objective

To assess recurrence in patients who would have been recommended to forego SLNB based on low-risk (Class 1A) 31-GEP results. We assessed whether these patients experienced any recurrence, particularly early recurrences, regardless of whether an SLNB was performed or SLNB positivity.

‍

methods

The DECIDE study is a prospective, multi-center study evaluating SLNB-eligible patients with T1-T2 tumors who underwent 31-GEP testing. Conducted across 22 institutions from May 2020 to May 2022, the study included patients whose clinicians considered SLNB and ordered the 31-GEP test for clinical decision-making. Data collection included 31-GEP results, SLNB performance, and recurrence outcomes, recorded through chart reviews and participant follow-ups at six-month intervals. This analysis focuses on early recurrence-free survival (RFS) in patients with Class 1A 31-GEP results who opted out of SLNB, ensuring these patients were not harmed by avoiding the procedure.

‍

Results

The current study demonstrates that patients with a Class 1A result may safely forgo the SLNB procedure. No patients had a recurrence within the study period, regardless of SLN status, supporting the clinical value of the 31-GEP test in guiding patient care.

‍

Would you like to talk more about
data related to TissueCypher?

Contact Us